Received 07/14/2023 Review began 07/20/2023 Review ended 07/27/2023 Published 07/30/2023

© Copyright 2023

Satyanarayana Killampalli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Preemptive Analgesic Efficacy of Dexamethasone and Diclofenac in Mitigating Post-surgical Complications After Mandibular Third-Molar Surgery: A Systematic Review

Dr.Yashwanth V. Satyanarayana Killampalli 1 , Monal Yuwanati 2 , Murugesan Krishnan 1 , Santhosh P. Kumar 1 , Melvin George 1 , Saravanan Lakshmanan 1

1. Oral and Maxillofacial Surgery, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 2. Oral Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND

Corresponding author: Saravanan Lakshmanan, saravananl.sdc@saveetha.com

Abstract

Mandibular third-molar extraction is a frequently executed minor oral surgical procedure, with a subsequent recovery period lasting several days. Typically, preemptive administration of non-steroid anti-inflammatory drugs (NSAIDs) and steroids has been employed, resulting in a notable decrease in postoperative complications like pain, facial swelling, trismus, and alveolar osteitis. This systematic review's primary goal was to investigate the efficacy of preemptive analgesia with dexamethasone and diclofenac in minimizing the post-surgical complications following the surgical extraction of the mandibular third molars. The systematic search was carried out to identify relevant literature in digital databases including PubMed®, Cochrane Library, Web of Science, and Scopus, from January 1990 to January 2022. The search used specific keywords. The randomized clinical trials assessing the efficacy of dexamethasone and diclofenac or dexamethasone alone compared to diclofenac or placebo as preemptive analgesics were considered inclusion criteria for this systematic review. Case reports, literature reviews, letters to the editor, and non-English publications were not included. Two authors screened the titles and abstracts, and articles fulfilling the study criteria were included. After reading the full text and data collection, analysis was performed. The included article's bias was evaluated by the Risk of Bias 2 (RoB 2) tool. A digital database search yielded a total of 207 articles. After excluding duplicates and articles written in languages other than English, 90 were removed. Based on the title and abstract, out of 177, 95 studies were excluded. After full-text reading of 22 articles. 17 were eliminated because they did not meet the inclusion and exclusion criteria. The remaining five studies were found eligible and included in the systematic review. Four studies were of low risk, while one study had some concerns. Two studies evaluated the combination of dexamethasone with diclofenac, while three evaluated dexamethasone alone. Total samples included samples of 436 third-molar surgeries in 420 patients. There was a substantial decrease in the mean pain score and swelling measurement when diclofenac alone was compared with coadministration of diclofenac and dexamethasone. Preemptive administration of dexamethasone and diclofenac has been shown to effectively reduce pain and facial swelling, with the exception of trismus, in third-molar surgeries when compared to diclofenac alone. As a result, it is recommended to administer these drugs prior to the commencement of third-molar extraction. However, further research is mandatory, specifically good quality randomized controlled trials involving large cohorts, in order to assess any significant variations and validate these findings.

Categories: Pain Management, Quality Improvement, Dentistry **Keywords:** impacted third molars, diclofenac sodium, dexamethasone, pre-emptive analgesia, third molar surgery

Introduction And Background

Mandibular third-molar surgery's most commonly faced problem is moderate-to-severe acute postoperative sequelae such as pain, swelling, and reduced mouth opening or trismus. Many clinicians tried to reduce these complications with routinely used non-steroid anti-inflammatory drugs (NSAIDs), however with limited success. This necessitates an alternate approach to managing the previously mentioned complications. In dentistry and medicine, NSAIDs have made a major impact on the management of postoperative pain. Prior to surgical trauma, NSAIDs have well-established mechanisms for their efficacy. The first advantage may be pharmacokinetic in nature. With the preemptive administration of NSAIDs prior to the onset of pain, drug absorption would have begun and therapeutic blood levels would have been reached prior to the onset of pain. Second, the presence of a cyclooxygenase inhibitor at the surgical site could decrease the secretion of prostaglandins and prostacyclins, which are linked to hyperalgesia and edema. Corticosteroids like dexamethasone are another preventive measure for minimizing postoperative edema and trismus after third-molar extractions. Postoperative edema may be caused to some extent by the conversion of phospholipids to arachidonic acid by phospholipase A2 and the subsequent production of inflammatory mediators including leukotrienes, prostacyclins, prostaglandins, and thromboxanes A2. Steroid use may hinder the initiation of this process. Schultze-Mosgau et al. researched the combined use of

How to cite this article

Satyanarayana Killampalli D V, Yuwanati M, Krishnan M, et al. (July 30, 2023) Preemptive Analgesic Efficacy of Dexamethasone and Diclofenac in Mitigating Post-surgical Complications After Mandibular Third-Molar Surgery: A Systematic Review. Cureus 15(7): e42709. DOI 10.7759/cureus.42709

ibuprofen and methylprednisolone for pain alleviation and found this combination possesses effective analgesic and anti-inflammatory properties [1]. He reported that a single dose of a glucocorticoid suppresses circulating levels of cortisol and beta-endorphin and lowers tissue levels of bradykinin. As known, bradykinin and kallidin are the two kinins that act both separately and synergistically with the arachidonic acid pathway to produce both hyperalgesia and increased vascular permeability.

Additionally, oral surgery clinical trials have proven the hypothesis that preemptive NSAIDs and corticosteroids prove beneficial in deferring and preventing numerous postoperative complications. The interactions between the mechanisms of action of NSAIDs and steroids suggest that combination therapy could offer anti-inflammatory and pain relief without adverse effects. However, the evidence in the literature regarding their efficacy is limited. Thus, it is important to find evidence of the effectiveness of the combination of dexamethasone and diclofenac or dexamethasone alone in reducing postoperative complications of third-molar surgery.

Review

The study protocol and research question

This systematic review was reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist [2]. The research question of the systematic review was "Is preemptive analgesia with dexamethasone and diclofenac effective in lowering postoperative discomfort like pain, swelling, and trismus following mandibular third molar surgery." The population, intervention, control, and outcome (PICO) elements of the systematic review are shown in Table 1.

| Elements | PICO |
|--------------|---|
| Population | Patients undergoing mandibular third molar surgery, impaction, wisdom tooth surgery |
| Intervention | Dexamethasone and diclofenac, dexamethasone |
| Comparison | Placebo, without any analgesics, diclofenac |
| Outcome | Postoperative control of pain, swelling, trismus |

TABLE 1: PICO elements of the systematic review

PICO, population, intervention, control, and outcome

The comprehensive search was carried out in digital databases such as PubMed, Web of Science, Scopus, and Cochrane Library until January 2022. The selection criteria included controlled clinical trials and randomized clinical trials utilizing dexamethasone with or without diclofenac, comparing them to diclofenac placebo as preemptive analgesics. No age, gender, or demographic restrictions were applied. However, studies published in languages other than English were excluded. The inclusion and exclusion criteria for the study are provided in Table 2.

| Inclusion | Exclusion |
|---|--|
| Study types: randomized controlled trials and clinical trials | Study types: case reports/case series |
| Publications in the English language | Publications other than the English language |
| Participants undergoing surgical extraction of mandibular third molar | Third molar extraction along with pathologies |
| Intervention: diclofenac and dexamethasone as a combination or alone as preemptive analgesia in lower third molar surgery | Studies in which other NSAIDs combination with any other steroids or drugs were used |
| Comparison: placebo, without any analgesics, any other analgesics as preemptive analgesia | |
| Outcome measures: postoperative pain, swelling, trismus | |

TABLE 2: Inclusion and exclusion criteria

NSAIDs, non-steroid anti-inflammatory drugs

Search Strategy and Sources

The search strategy was prepared using PICO, and databases (PubMed, Cochrane Database of Systematic Review, Scopus, and Web of Science) were searched. The search terms included "randomized controlled trial," "controlled clinical trial," "third molar surgery," "mandibular third molar impaction," "dexamethasone," "diclofenac," "preemptive," "pain," "swelling," "trismus," and "postoperative complications." In addition, the British Journal of Oral and Maxillofacial Surgery, International Journal of Oral and Maxillofacial Surgery, Journal of Oral and Maxillofacial Surgery, Journal of Cranio Maxillofacial Surgery, and Quintessence International Journals were searched for additional relevant papers. Further cross-references were manually searched.

Two authors independently searched the included databases. Duplicated studies across databases were removed. Furthermore, two authors independently screened titles to identify relevant studies based on predetermined inclusion and exclusion criteria. Any discrepancies between the authors were resolved through discussion. Abstracts were evaluated when title information was insufficient. The final study inclusion was determined independently by both authors after full-text reading. Additional studies were identified through scrutiny of reference lists from full-text articles. After finalizing the inclusion of the study in the systematic review, data was extracted. The extracted data included author, journal, year, study design, sample size, participants and groups, methodology, outcome assessment, and results and conclusions. Figure 1 depicted the search strategy according to the PRISMA guidelines. The outcome of interest in the systematic review included evaluating post-surgical pain, facial swelling, and reduction in mouth opening using various measurements and scales.

Identification of new studies via databases and registers




FIGURE 1: PRISMA flowchart

PRISMA, preferred reporting items for systematic reviews and meta-analyses

Risk of Bias and Quality Assessment

The risk of bias for each study was evaluated independently by the review authors, and discrepancies regarding the risk of bias were resolved through discussion. Quality assessment was done using the Cochrane RoB (Risk of Bias) 2 tool [3].

Summary Synthesis

The descriptive analysis was carried out. The results were summarized by grouping the information. The results are categorized into outcomes, i.e., pain, swelling, and trismus. Furthermore, descriptive analyses were performed for the type of drug, dose, and time of outcome analysis.

Results

Study Selection

The MeSH (Medical Subject Headings) terms/keywords were used to conduct a digital search in the four search engines: PubMed®, Cochrane Library, Web Of Science, and Scopus, which obtained a total of 207 articles. Seventy articles were excluded due to duplication and 20 articles were removed due to other languages. The remaining article abstracts were reviewed independently. After reading titles and abstracts, 95 articles were excluded; among them 22 articles remained, and 17 were excluded after reading the full text [4-20]. Five articles remained for the final assessment.

Study Characteristics

Table 3 and Table 4 contain a detailed description of the included studies' characteristics and an evaluation of their outcomes using clinical parameters. Five included studies were randomized clinical trials conducted

in Nigeria and Brazil. Total samples included 436 third molar surgeries in 420 patients. The age of the patients was between 16 years and above. A total of 219 males and 201 females were included. Three patients were excluded. Two studies were double-blinded studies, one study was a single-blinded study, and one study was split mouth triple-blinded study. and another one is an open-label pilot study. With the exception of the study conducted by Simone et al., all other studies assessed pain, swelling, and mouth opening as outcome measures. However, Simone et al. focused solely on evaluating pain and the total amount of rescue medications used [21].

| Author, year | Journal, country | Type of study | Sample size, Age | Groups a form | and drug usage, |
|--|---|---|--|---------------|--|
| Babatund Olamide Bamgbose et al., 2005 [22] | Biomed Central Journal, Nigeria | Prospective randomized double-blind study | Sample size: 100; Age: 16 years and above; 52 men and | 2 Groups | Group 1: Dexa 8 mg IV and Diclo 50 mg, Oral |
| | | | 48 female | | Group 2: Diclo 50 mg, Oral |
| Babatunde Olamide Bamgbose et al., 2006 [23] | Current Therapeutic Research, Nigeria | Prospective, randomized, open-label pilot study | Sample size: 150, age: 18 and 45 years; 75 men and 76 female | 3 Groups | Group 1: Dexa 8 mg and Diclo 50 mg, Oral |
| | | | | | Group 2: Dexa 8 mg and Para 1 g, Oral |
| | | | | | Group 3- Diclo 50 mg, Oral |
| | Brazilian Oral Research, Brazil | Randomized, double-blind, parallel, placebo- controlled study | Sample size: 54, age: 16-28 years; 19 men and 35 female | 3 Groups | Group 1- Diclo 50 mg, Oral |
| José Leonardo Simone et al., 2013 [21] | | | | | Group 2- Dexa 8 mg, Oral |
| 1-11 | | | | | Group 3: Placebo |
| | Journal of Oral and Maxillofacial Surgery, Brazil | Split-mouth, RCT, triple- blind study | Sample size: 30, age: 18-35 years; 3 male and 12 female | 2 Groups | Group 1: Dexa 8 mg, Oral |
| Thiago César Lima et al., 2017 [24] | | | | | Group 2: Diclo 50 mg with codeine 50 mg, Oral |
| Rakesh B. Nair et al., | The Journal of Contemporary Dental | Randomized controlled clinical trial | Sample size: 100; Age: 18 and | 2 Groups | Group 1: Dexa 4 mg, sub-mucosal |
| 2013 [25] | Practice | | above | | Group 2: control group, no drug |

TABLE 3: Characteristics of included studies

RCT, randomized control trial; Dexa, dexamethasone; Diclo, diclofenac sodium; Para, paracetamol

| Study | Method of evaluation | Mean values | Outcomes |
|-------|---|-----------------------------|----------|
| | | Group 1: day 1, 0.62±0.6 | |
| | Pain: 4-point Likert type pointer CRS (mean±standard | Group 1: day 2, 0.5±0.5 | |
| | deviation) | Group 2: Day 1, 1.64±0.9 | |
| | | Group 2: Day 2, 1.3±0.62 | |
| | | | |

| abalanda ampidose et uanga a seq (mean:standard (wiston) Facial swelling in millimeters: using a seq (mean:standard (wiston) forup 1: Day 2, 31,0158 boomen insolution: downline using in millimiters: excluding throws relief. Results were statistically (roup 2: Day 1, 31,711.6 Wouth-opening in millimeters: (mean:standard deviation) Group 1: Day 2, 30,4158 seq (Landing throws relief. Results were statistically (roup 2: Day 1, 31,721.6 Wouth-opening in millimeters: (mean:standard deviation) Group 1: Day 2, 30,411.02 Group 1: Day 2, 30,411.02 Group 1: May 2, 56,01 Group 2: Day 1, 39,2411.3 Group 1: May 2, 56,01 Group 2: None, 12 (24) Group 2: None, 12 (24) Group 2: None, 12 (24) Group 2: None, 12 (24) Group 2: Moderate, 7(14) Group 2: Moderate, 7(14) Group 3: Moderate, 11 (22) Group 2: Moderate, 7(14) Group 2: Moderate, 7(14) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 2: Group 3, 30, 1(16) Japain 4: Applint Likert type point mandbase et in, 2000 (2000) Bay 1: Group 3, 31, 7(16) Bay 1: Group 3, 31, 7(16) Bay 1: Group 3: Moderate, 11 (22) Group 2: Group 3, 30, 1(16) Day 1: Group 3, 30, 2(11,3) Bay 2: Group 1, 31, 0, (16) Day 1: Group 3, 30, 2(11,3) Day 2: Group 3, 30, 2(11,3) Bay 1: Group 2, 30, 2(11,3) <th>Debaturd</th> <th></th> <th>Group 1: Day 1, 30.9±1.6</th> <th>Devenethesens and dislatence combination</th> | Debaturd | | Group 1: Day 1, 30.9±1.6 | Devenethesens and dislatence combination | |
|--|--|--|-----------------------------|--|--|
| anglobes et | Babatund Olamide Bamgbose et al., 2005 [22] | using a tape (mean±standard | | | |
| number of the second | | | | excluding trismus relief. Results were statistically significant in pain and swelling | |
| Abult-opening in millimeters: Using vermic caliper (mean:standard deviation) Group 1: Day 2, 38, 141,0.65 Group 2: Day 2, 38, 141,0.65 Group 2: Day 2, 38, 141,0.65 Group 2: Day 2, 38, 141,0.65 Group 2: Day 2, 38, 141,0.65 Group 1: Mone, 22 (44) Group 1: Mone, 22 (44) Group 1: Mone, 22 (44) Group 1: Mone, 22 (44) Group 2: Mone, 12 (24) Group 2: Mone, 12 (24) Group 2: Mone, 12 (24) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Group 1, 30.0 (15) Day 1: Group 3, 30.1 (16) Day 2: Group 1, 30.1 (16) Day 2: Group 1, 30.1 (16) Day 2: Group 1, 30.1 (16) Day 2: Group 3, 32.0 (15).0 Day 1: Group 3, 30.2 (11.3) Day 1: Group 3, 30.2 (11.3) Mouth opening: vernist calendard deviation) Group 2: Group 1, 30.1 (16) Day 2: Group 3, 30.2 (11.3) Day 1: Group 3, 30.2 (11.3) Day 2: Group 3, 30.2 (11.3) Day 2: Group 3, 30.2 (11.3) Day 2: Group 3, 30.2 (10.8) <t< td=""><td></td><td></td></t<> | | | | | |
| Badit-opening in milimeters caller (rean-standard deviation) Group 1: Day 2, 38, 121.005 Group 2: Day 1, 30, 2211.3 Group 2: Day 2, 30, 641.002 Group 1: Mone, 22 (44) Group 1: Mone, 22 (44) Group 1: Mode, 25 (50) Group 1: Mode, 25 (50) Group 2: Mode, 23 (44) Group 2: Mode, 23 (44) Group 2: Mode, 23 (44) Group 2: Mode, 23 (44) Group 2: Mode, 23 (44) Group 2: Severe, 30 (44) Group 2: Mode, 23 (44) Group 2: Severe, 32 (44) Group 2: Mode, 23 (44) Group 2: Severe, 32 (44) Group 2: Mode, 23 (44) Group 2: Severe, 32 (44) Group 3: Severe, 4 (8) Mode, 25 (24) Mode, 23 (45) Group 3: Mode, 23 (45) By 1: Group 3, 30, 10 (16) Day 1: Group 3, 30, 10 (16) Day 1: Group 3, 30, 10 (16) Day 1: Group 3, 30, 20 (15) By 1: Group 3, 30, 20 (15) Day 1: Group 3, 30, 20 (15) Day 2: Group 3, 30, 20 (16) Day 1: Group 3, 30, 20 (15) Day 2: Group 3, 30, 20 (15) Day 1: Group 3, 30, 20 (15) Day 2: Group 3, 30, 20 (15) Day 1: Group 3, 30, 20 (15) Day 2: Group 3, 30, 20 (15) Day 1: Group 3, 30, 20 (15) Day 2: Group 3, 30, 20 (15) | | | | | |
| biolog wenier caliper (meanestandard deviation) Group 2: Doi y1.30.2:11.3 Group 2: Duy 2.30.2:10.2 Group 2: None, 22 (4) Group 1: None, 22 (4) Group 1: None, 22 (4) Group 2: None, 11 (2) Group 2: None, 11 (2) Group 2: None, 11 (2) Group 2: None, 11 (2) Group 2: Moderate, 3(6) Group 2: Moderate, 7(14) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Moderate, 11 (22) Group 3: Severe, 0 Group 3: Moderate, 11 (22) Group 3: Severe, 0 Group 3: Moderate, 11 (22) Group 3: Severe, 4(8) Group 3: Severe, 4(8) Bay 1: Group 3: Severe, 4(8) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Group 2: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) Day 1: Group 3: 0.00 (1.6) | | Using vernier caliper | | | |
| induction in the number of the period is of the per | | | | | |
| Babitunde amglose et militimaters (meanisstandard deviation) Group 1: None, 22 (44) Group 1: Mid, 25 (50) Group 1: Mid, 25 (50) Group 1: Severe, 0 Group 2: None, 11 (22) Group 2: Mid, 22 (44) Group 2: Mid, 23 (46) Group 3: None, 12 (24) Group 3: Mid; 23 (46) Group 3: Mid; 23 (46) Babitunde amglose et minde amglose et minde amglose et minde amglose et amglose et minde amglose et min | | | | | |
| Pair: 4-point Liker (type point GRS in percentage, Day 1) Group 1: Mid, 25 (6) Group 1: Severe, 0 Group 2: None, 11 (22) Group 2: None, 11 (22) Group 2: Mid, 32 (64) Group 2: None, 12 (24) Group 3: None, 12 (24) Group 3: None, 12 (24) Group 3: Mid, 23 (46) Group 3: None, 12 (24) Group 3: Mid, 23 (46) Group 3: None, 12 (24) Group 3: Mid, 23 (46) Group 3: None, 12 (24) Group 3: None, 12 (24) Group 3: None, 12 (24) Group 3: None, 12 (24) Group 3: None, 12 (24) Group 3: None, 12 (24) Group 3: Severe, 4 (8) Group 3: Severe, 4 (8) Bay: Group 3. Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Severe, 10 (30) Group 3: Group 3: 3: 0: (1: 30) Group 3: Group 3: 3: 0: (1: 30) Group 3: Group 3: 3: 0: (1: 30) Group 3: 3: 0: (1: 30) Group 3: Group 3: 3: 0: (1: 30) Group 3: 3: | | | | | |
| Pair: 4-point Likert type point (RS in percentage, Day 1) Group 1: Moderale, 3(6) Pair: 4-point Likert type point (RS in percentage, Day 1) Group 2: Mone, 11 (22) Pair: 4-point Likert type point (RS in percentage, Day 1) Group 2: Moderale, 7 (14) Group 2: Moderale, 7 (14) Group 2: Moderale, 7 (14) Group 3: Moderale, 11 (22) Group 3: Moderale, 7 (14) Group 3: Moderale, 7 (14) Group 3: Moderale, 11 (22) Group 3: Moderale, 11 (22) Group 3: Moderale, 11 (22) Group 3: Severe, 4 (8) Day 1: Group 3: Severe, 4 (8) Day 1: Group 3: 3.01 (16) Day 1: Group 3: 3.01 (16) Day 2: Group 3: 3.01 (16) Day 2: Group 3: 3.02 (15) Group 2: Group 3: 3.02 (1.5) Day 1: Group 3: 3.02 (1.6) Mouth opening: vernier caliple in millimeters (meanstander deviation) Day 1: Group 3: 3.02 (1.3) Mouth opening: vernier caliple in millimeters (meanstander deviation, pain scores in the entre periot) Day 1: Group 3: 3.02 (1.3) Day 2: Group 3: 3.01 (1.0) Day 2: Group 3: 3.01 (1.0) Day 2: Group 3: 3.01 (1.0) Day 2: Group 3: 3.01 (1.0) Day 2: Group 3: 3.01 (1.0) Day 2: Group 3: 3.01 (1.0) Day 2: Group 3: 3.01 (1.0) Day 2: Group 3: 3.01 (1.0) Day 2: | | | | | |
| Babatunde Ismida Group 1: Severe, 0 Group 2: None, 11 (22) Group 2: Mid, 32 (64) Group 2: Mid, 32 (64) Group 2: Severe, 23(46) Group 3: Mid, 23 (44) Group 3: Mid, 23 (46) Day 1: Group 3: Mid, 23 (46) Day 2: Group 3: Mid, 23 (42) Day 2: Group 3: Mid, 10:10 Day 2: Group 3 | | | | | |
| Base of the second se | | | | | |
| Pair: 4-point Liker type point CRS in percentage, Day 1 Group 2: Midt, 32 (64) Group 2: Severe, 23(46) Group 3: None, 12 (24) Group 3: Midt, 23 (46) Group 3: Midt, 23 (46) Group 3: Moderate, 7 (14) Group 3: Midt, 23 (46) Group 3: Midt, 23 (46) Group 3: Midt, 23 (46) Group 3: Midt, 23 (46) Group 3: Midt, 23 (46) Group 3: Moderate, 11 (22) Group 3: Midt, 23 (46) Facial swelling: a tape in (meanstandard deviation) Day 1: Group 1, 30.0 (1.6) Day 2: Group 3, 31, 7 (1.6) Day 2: Group 3, 31, 7 (1.6) Day 2: Group 3, 31, 7 (1.6) Day 2: Group 3, 32, 0 (1.5) Day 2: Group 3, 32, 0 (1.5) Day 1: Group 7, 30.8, 0 (1.2) Day 2: Group 3, 32, 0 (1.5) Day 2: Group 3, 32, 2 (11.3) Day 2: Group 3, 38, 1 (1.6, 1) Day 2: Group 3, 38, 0 (1.6, 1) Day 2: Group 3, 36, 0 (1.0) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1) Day 2: Group 3, 36, 0 (1.0, 1)< | | | | | |
| pair. + point Clear type points Group 2: Moderate, 7 (14) Group 2: Severe, 23(46) Group 3: None, 12 (24) Group 3: Mild, 23 (46) Group 3: Mild, 23 (46) Group 3: Severe, 4 (8) Group 3: Severe, 4 (8) amglose et amglose et amglose et millimede amglose et millimede Day 1: Group 1, 30.9 (1.6) Day 3: Severe, 4 (8) Facial swelling: a tape in (mean:standard deviation) Day 1: Group 3, 31.7 (1.6) Day 2: Group 3, 32.0 (1.5) Day 2: Group 3, 32.0 (1.5) Day 2: Group 3, 32.0 (1.5) Day 2: Group 3, 32.0 (1.5) Day 2: Group 3, 32.0 (1.5) Day 1: Group 3, 39.2 (11.3) Day 2: Group 3, 39.2 (11.3) Mouth opening: vernier caliper in millimeters (mean:standard deviation) Day 1: Group 3, 39.2 (11.3) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Dich. Z.70.7 The dexamethasone group had lower pain intensity compared to d | | | | | |
| abatunde landice amgbose et ., 2006 [23] Group 2: Severe, 23(46) Group 3: None, 12 (24) Group 3: None, 12 (24) Group 3: Noderate, 11 (22) Group 3: Noderate, 11 (22) Group 3: Severe, 4 (8) Group 3: Severe, 4 (8) and facial swelling significantly compared to the other groups. Trismus relief was similar. page 1: Group 1: Group 3: 0.0 (1.6) Day 1: Group 2: 30.9 (1.5) Day 2: Group 3.31.7 (1.6) Day 2: Group 2: 31.2 (1.5) Day 2: Group 3.32.0 (1.5) Day 2: Group 3.32.0 (1.5) Day 2: Group 3.32.0 (1.5) Day 2: Group 3.38.0 (10.0) Day 2: Group 3.38.0 (10.0) Mouth opening: vernier caliper in milimeters (mean:standard deviation) Day 1: Group 2.38.8 (12.6) Day 2: Group 2.38.1 (10.8) Day 2: Group 3.36.0 (10.0) Day 2: Group 3.36.0 (10.0) Day 2: Group 3.36.0 (10.0) Day 2: Group 3.36.0 (10.0) Day 2: Group 3.36.0 (10.0) The dexamethasone group had lower pain intensity compared to diclofenace and placebo. Not much difference in total rescue medication and facial swelling significantly compared to diclofenace and placebo. Not much difference in total rescue medication and facial swelling significantly compared to diclofenace and placebo. Not much difference in total rescue medication and facial swelling significantly compared to diclofenace and placebo. Not much difference in total rescue medication and facial swelling significantly compared to diclofenace and placebo. Not much difference in total rescue medication and facial sw | | | | | |
| Abatande lamide amgbose et i, 2006 [23] Base Leonards into e et al. 11] Pain: VAS (meanisstandard deviation) Pain: VAS (meanis | | CRS in percentage, Day 1 | | | |
| Abatande lamide amglose et 1, 2006 [23] Abatande amglose et 1, 2006 [23] Abatande lamide amglose et 1, 2006 [24] Abatande Heanistandard deviation) Facial swelling: tappe in femenistandard deviation) Abatande to pering: vernier calipe invillimeters (meanistand deviation) apt 1: Group 3, 30.0 (1.5) Day 1: Group 3, 30.0 (1.5) Day 2: Group 3, 32.0 (1.5) Day 2: Group 3, 32.0 (1.5) Day 1: Group 3, 32.0 (1.5) Day 2: Group 3, 30.0 (10.0) Day 3: Group | | | Group 2: Severe, 23(46) | | |
| Abatunde Hamide amgbose et 1, 2006 [23] Facial swelling: a tape in [mean±standard deviation] Facial swelling: a tape in [maintimeters (mean±standard deviation] Facial swelling: a tape in [maintimeters (mean±standard facial swelling: a tape in [maintimeters (mean±standard deviation] Facial swelling: a tape in [maintimeters (mean±standard facial swelling: a tap | | | Group 3: None, 12 (24) | | |
| Babalande lamide amgbose et in, 2006 [23] Image: Comp 3: Severe, 4 (B) Pay 1: Group 1: 30.9 (1.6) Dexamethasone and diciofenac K reduced pain and facial swelling significantly compared to the other groups. Trismus relief was similar. 2006 [23] Day 1: Group 2: 30.9 (1.5) Day 1: Group 2: 30.9 (1.5) Day 2: Group 2: 31.2 (1.5) Day 2: Group 2: 31.2 (1.5) Day 2: Group 2: 33.2 (1.5) Day 1: Group 2: 38.8 (12.6) Day 1: Group 2: 30.9 (1.5) Day 1: Group 2: 30.9 (1.5) Day 2: Group 2: 31.2 (1.5) Mouth opening: vernier calipe in millimeters (mean±standard deviation) Day 1: Group 1: 30.9 (1.10.1) Day 2: Group 2: 38.8 (12.6) Day 2: Group 2: 38.1 (10.8) Day 2: Group 3: 30.0 (10.0) Day 2: Group 3: 30.0 (10.0) Day 2: Group 2: 38.1 (10.8) Day 2: Group 2: 38.1 (10.8) Day 2: Group 3: 30.0 (10.0) Dexa, 1: 9:0.4 Placebo: 3.0:0.5 The deviamethasone group had lower pain intensity compared to diclofenac and placebo. Seé Leonardo imone et al. [1] The total amount of rescue medications of paracetand used (mean±standard deviation) Dexa, 2: 1::3.4 Placebo: 3.0:0.4 Diclo, 1:7±2:7 The total amount of rescue medications of paracetand used (mean±standard Diclo, 1:7±2:7 Naruet difference in | | | Group 3: Mild, 23 (46) | | |
| lamide amgbose et , 2006 [23] Age and facial swelling significantly compared to the other groups. Trismus relief was similar. Pacial swelling: a tape in (mean±standard deviation) Facial swelling: a tape in (mean±standard deviation) Facial swelling: a tape in (mean±standard deviation) | Babatunde | | Group 3: Moderate, 11 (22) | | |
| h, 2006 [23] h, 2006 [23] Facial swelling: a tape in (mean±standard deviation) Pay 1: Group 2, 30.9 (1.5) Day 1: Group 3, 31.7 (1.6) Day 2: Group 1, 31.0 (1.6) Day 2: Group 2, 31.2 (1.5) Day 1: Group 2, 38.0 (10.0) Day 1: Group 3, 30.0 (11.2) Day 1: Group 3, 30.2 (11.3) Day 1: Group 3, 30.2 (11.3) Day 2: Group 1, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 3: Group 3, 36.0 (10 | Olamide | | Group 3: Severe, 4 (8) | | |
| Bacial swelling: a tape in (mean±standard deviation) Day 1: Group 3, 31.7 (1.6) Day 2: Group 1, 31.0 (1.6) Day 2: Group 2, 31.2 (1.5) Day 2: Group 3, 32.0 (1.5) Day 1: Group 3, 32.0 (1.5) Day 1: Group 3, 32.0 (1.5) Day 1: Group 3, 32.0 (1.5) Day 1: Group 3, 39.2 (11.2) Day 1: Group 3, 39.2 (11.3) Day 2: Group 1, 38.1 (10.1) Day 2: Group 1, 38.1 (10.1) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Dexa, 1.9±0.4 Pacebo, 3.0±0.5 Diclo, 2.7±0.7 Diclo, 2.7±0.7 Dexa, 2.1±3.4 The total amount of rescue medications of paracetamol used (mean±standard deviation) Dexa, 2.1±3.4 Placebo, 3.0±4.0 Diclo, 1.7±2.7 Diclo, 1.7±2.7 Dexa, 0.1±2.7 | Bamgbose et al., 2006 [23] | | Day 1: Group 1, 30.9 (1.6) | other groups. Trismus relief was similar. | |
| Packar sweening, a table in (mean±standard deviation) Day 2: Group 1, 31.0 (1.6) Day 2: Group 2, 31.2 (1.5) Day 2: Group 3, 32.0 (1.5) Day 1: Group 1, 36.0 (11.2) Day 1: Group 2, 38.8 (12.6) Mouth opening: vernier caliper in millimeters (mean±standard deviation) Day 1: Group 3, 39.2 (11.3) Day 2: Group 2, 38.1 (10.1) Day 2: Group 1, 38.1 (10.1) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Dexa, 1.9±0.4 Pain: VAS (mean±standard deviation, pain scores in the entire period) Dexa, 1.9±0.4 Placebo, 3.0±0.5 Diclo, 2.7±0.7 The total amount of rescue medications of paracetamol used (mean±standard deviation) Dexa, 2.1±3.4 Placebo, 3.0±4.0 Diclo, 1.7±2.7 Diclo, 1.7±2.7 Group 1, | | | Day 1: Group 2, 30.9 (1.5) | | |
| base base <td< td=""><td></td><td>Day 1: Group 3, 31.7 (1.6)</td></td<> | | | Day 1: Group 3, 31.7 (1.6) | | |
| h Day 2: Group 3, 32.0 (1.5) bay 1: Group 1, 36.0 (11.2) Day 1: Group 2, 38.8 (12.6) Day 1: Group 3, 32.2 (11.3) Day 2: Group 1, 38.1 (10.1) Day 2: Group 1, 38.1 (10.1) Day 2: Group 2, 38.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Pacebo, 3.04.0.5 Day 2: Group 3, 30.0 (10.0) Pacebo, 3.04.0.5 Day 2: Group 3, 30.0 (10.0) Pacebo, 3.04.0.5 Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Pacebo, 3.04.0.5 Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Pacebo, 3.04.0.5 Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) Day 2: Group 3, 30.0 (10.0) | | | Day 2: Group 1, 31.0 (1.6) | | |
| And the definition of the period Day 1: Group 1, 36.0 (11.2) Day 1: Group 2, 38.8 (12.6) Day 1: Group 2, 38.8 (12.6) Day 1: Group 3, 39.2 (11.3) Day 2: Group 1, 38.1 (10.1) Day 2: Group 1, 38.1 (10.1) Day 2: Group 2, 38.1 (10.8) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 1, 38.1 (10.1) Day 2: Group 3, 36.0 (10.0) Day 2: Group 1, 38.1 (10.1) Day 2: Group 3, 36.0 (10.0) Day 2: Group 1, 38.1 (10.1) Dico, 2.7±0.7 Day 2: Group 1, 38.1 (10.1) Day 2: Group 3, 36.0 (10.0) Day 2: Group 1, 38.1 (10.1) Day 2: Group 3, 36.0 (10.0) Day 2: Group 1, 38.1 (10.1) Dico, 2.7±0.7 Dico, 1.7±2.7 Dico, 1.7±2.7 Dico, 1.7±2.7 | | | Day 2: Group 2, 31.2 (1.5) | | |
| And the set of the set | | | Day 2: Group 3, 32.0 (1.5) | | |
| Mouth opening: vernier caliper millimeters (mean±standard deviation) Day 1: Group 3, 39.2 (11.3) Day 2: Group 1, 38.1 (10.1) Day 2: Group 2, 38.1 (10.8) Day 2: Group 2, 38.1 (10.8) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Dexa, 1.9±0.4 Placebo, 3.0±0.5 Placebo, 3.0±0.5 Diclo, 2.7±0.7 Diclo, 2.7±0.7 Dexa, 2.1±3.4 Placebo, 3.0±4.0 Dexa, 2.1±3.4 Placebo, 3.0±4.0 Dexa, 2.1±3.4 Placebo, 3.0±4.0 Dexa, 2.1±3.4 Placebo, 3.0±4.0 Dexa, 0.9±0.5 Diclo, 1.7±2.7 Diclo, 1.7±2.7 Placebo, 3.0±4.0 Diclo, 1.7±2.7 Diclo, 1.7±2.7 Diclo, 1.7±2.7 | | in millimeters (mean±standard | Day 1: Group 1, 36.0 (11.2) | | |
| in millimeters (mean±standard deviation) Day 2: Group 1, 38.1 (10.1) Day 2: Group 2, 38.1 (10.8) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Dexa, 1.9±0.4 Placebo, 3.0±0.5 Diclo, 2.7±0.7 The total amount of rescue medications of paracetamol used (mean±standard deviation) The total amount of rescue medications of paracetamol used (mean±standard deviation) The total amount of rescue medications of paracetamol used (mean±standard deviation) Dexa, 2.1±3.4 Placebo, 3.0±4.0 Diclo, 1.7±2.7 Group 1, Group 1, | | | Day 1: Group 2, 38.8 (12.6) | | |
| deviation) Day 2: Group 1, 38.1 (10.1) Day 2: Group 2, 38.1 (10.8) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Day 2: Group 3, 36.0 (10.0) Pain: VAS (mean±standard deviation, pain scores in the entire period) Dexa, 1.9±0.4 Placebo, 3.0±0.5 Diclo, 2.7±0.7 The total amount of rescue medications of paracetamol used (mean±standard deviation) Dexa, 2.1±3.4 Placebo, 3.0±4.0 Diclo, 1.7±2.7 Diclo, 1.7±2.7 The total amount of rescue medication of the paracetamol used (mean±standard deviation) Diclo, 1.7±2.7 Group 1, | | | Day 1: Group 3, 39.2 (11.3) | | |
| Image: basic learning basic learni | | | Day 2: Group 1, 38.1 (10.1) | | |
| pain: VAS (mean±standard deviation, pain scores in the entire period) Dexa, 1.9±0.4 Image: Constraint of the deviation, pain scores in the entire period) Image: Constraint of the deviation, pain scores in the entire period) Image: Constraint of the deviation, pain scores in the entire period) Image: Constraint of the deviation, pain scores in the entire period) Image: Constraint of the deviation of the deviat | | | Day 2: Group 2, 38.1 (10.8) | | |
| Pain: VAS (mean±standard deviation, pain scores in the entire period) Placebo, 3.0±0.5 Diclo, 2.7±0.7 The total amount of rescue medications of paracetamol used (mean±standard deviation) Diclo, 1.7±2.7 Placebo, 3.0±4.0 Diclo, 1.7±2.7 Group 1, Group 1, Placebo 2 | | | Day 2: Group 3, 36.0 (10.0) | | |
| beside Leonardo imone et al. deviation, pain scores in the entire period) Placebo, 3.0±0.5 The dexamethasone group had lower pain intensity compared to diclofenac and placebo. Not much difference in total rescue medication wong them. The total amount of rescue medications of paracetamol used (mean±standard deviation) Dexa, 2.1±3.4 The dexamethasone group had lower pain intensity compared to diclofenac and placebo. Not much difference in total rescue medication among them. Diclo, 1.7±2.7 Diclo, 1.7±2.7 Fracebo, 3.0±1,0 | José Leonardo | deviation, pain scores in the | Dexa, 1.9±0.4 | | |
| See Leonardo imone et al. Diclo, 2.7±0.7 intensity compared to diclofenac and placebo. Not much difference in total rescue medication among them. The total amount of rescue medications of paracetamol used (mean±standard deviation) Dexa, 2.1±3.4 Not much difference in total rescue medication among them. Diclo, 1.7±2.7 Diclo, 1.7±2.7 Group 1, | | | Placebo, 3.0±0.5 | | |
| Immone et al. The total amount of rescue medications of paracetamol used (mean±standard deviation) Dexa, 2.1±3.4 Not much difference in total rescue medication among them. Diclo, 1.7±2.7 Diclo, 1.7±2.7 Group 1, | | | Diclo, 2.7±0.7 | | |
| medications of paracetamol used (mean±standard deviation) Placebo, 3.0±4.0 Diclo, 1.7±2.7 Diclo, 1.7±2.7 | Simone et al. [21] | medications of paracetamol used (mean±standard | Dexa, 2.1±3.4 | Not much difference in total rescue medication | |
| deviation) Diclo, 1.7±2.7 Group 1, Group 1, | | | Placebo, 3.0±4.0 | anony mem. | |
| | | | Diclo, 1.7±2.7 | | |
| | | | | | |

| | | 24 hr | Group 2, 3.9±2.2 | |
|------------------|--|-------------------|-----------------------|---|
| | Pain: 10-point numerical rating scale (mean±standard | 48 hr | Group 1, 3.4±2.0 | |
| | deviation) | | Group 2, 5.2±2.1 | |
| | | 70 1 | Group 1, 3.1±2.6 | |
| | | 72 hr | Group 2, 4.0±2.4 | |
| | | 24 hr | Group 1, 0.52±0.3 | |
| | | 24 hr | Group 2, 0.11±0.7 | |
| | | 48 hr | Group 1, 0.77±0.5 | |
| | Swelling: using a tape measure by 3 pointer scale in | 40 11 | Group 2, 1.45±0.7 | |
| Thiago César | millimeters (mean±standard deviation) | 72 hr | Group 1, 0.60±0.4 | Dexamethasone provided better pain control and reduced swelling compared to sodium diclofenac |
| Lima et al. [24] | | | Group 2, 1.12±0.7 | with codeine. No difference in mouth opening and rescue analgesics between groups. |
| | | | Group1, 0.18±0.2 | |
| | | 7 days | Group 2, 0.28±0.3 | |
| | | 24 hr | Group 1, 16.6±9.9 | |
| | | 2411 | Group 2, 17.3±6.9 | |
| | | 48 hr | Group 1, 16.6±10.1 | |
| | Reduction in mouth opening in millimeters (mean±standard | | Group 2, 19.7±6.5 | |
| | deviation) | 72 hr | Group 1, 15.1±10.0 | |
| | | | Group 2, 17.2±7.1 | |
| | | 7 days | Group 1, 9.11±8.8 | |
| | | | Group 2, 10.0±7.0 | |
| | | 2nd postoperative | Group 1, 3.1±1.70 | |
| | Pain: 9-point VAS (mean±standard deviation) | day | Group 2, 3.73±1.56 | |
| | | 7th postoperative | Group 1, 1.27±1.11 | |
| | | day | Group 2, | |

| | Swelling: 3-pointer measurements scale (mean±standard deviation) | Group 1: 2nd postoperative day | 1.98±1.49 A point, 111.02±5.7 | |
|----------------|--|--------------------------------------|-------------------------------------|--|
| | | | B point, 133.57±10.3 | |
| | | Group 2: 2nd postoperative day | A point, 115±6.6 | |
| | | | B point, 137.9±10.5 | |
| Rakesh B. Nair | | Group 1: 7th postoperative day | A point, 110.8±5.7 | Submucosal dexamethasone reduces pain and |
| et al. [25] | | | B point, 130.8±20.0 | facial swelling more than the control group but no difference in reduction in mouth opening |
| | | Group 2: 7th postoperative day | A point, 113.6±6.2 | |
| | | | B point, 135.7±10.3 | |
| | | Preoperative | Group 1, 42.27±6.7 | |
| | | | Group 2, 43.12±6.7 | |
| | Reduction in mouth opening (mean±standard deviation) | 2nd postoperative day | Group 1, 3.73±1.5 | |
| | | | Group 2, 3.1±1.7 | |
| | | 7th postoperative | Group 1, 1.27±1.1 | |
| | | | Group 2, 1.98±1.4 | |

TABLE 4: Characteristics of included studies

CRS, category rating scale; VAS, visual analog scale

Pain Assessment

Evaluation of pain was done using a four-point Likert scale in two trials conducted by Bamgbose et al. [22,23,26]. In these two studies, postoperative pain assessment was performed on Day 1 and Day 2. However, in the 2005 study the postoperative pain was measured as a mean score whereas in the 2006 study, the postoperative pain was measured as a percentage. Both studies concluded that the combination of dexamethasone with diclofenac exhibited a significantly greater relief of postoperative pain (21). Their study concluded that the dexamethasone group exhibited lower postoperative pain intensity compared to both the diclofenac and placebo groups. Lima et al. and Rakesh B Nair et al. implemented a 10-point numerical rating scale to assess postoperative pain over a period of three days [24,25]. Lima et al. concluded that dexamethasone provided superior postoperative pain control compared to diclofenac [24]. Although, Rakesh B. Nair et al. found that dexamethasone alone demonstrated a reduction in postoperative pain over the control group [25].

Swelling Assessment

Assessment of facial swelling was done by a tape measure kept from the tragus-gonion to the other side tragus in two studies conducted by Bamgbose et al. [22,23]. In both studies, the assessment was conducted on Day 1 and Day 2 to measure postoperative swelling, recorded as the mean score±standard deviation. Both studies concluded that the combination of dexamethasone with diclofenac exhibited a significantly greater

reduction of postoperative swelling compared to diclofenac alone. Lima et al. and Rakesh B Nair et al. utilized a tape measure and a three-point measurement scale to evaluate facial swelling over a period of seven days [24,25]. Lima et al. concluded that dexamethasone provided superior control of swelling compared to diclofenac [24]. Although, Rakesh B. Nair et al. concluded that dexamethasone demonstrated a reduction in swelling over the control group [25].

Trismus Assessment

Trismus, or restricted mouth-opening, was evaluated by measuring interincisal distance in all included studies. Two studies conducted by Bangbose et al. used a vernier calibrated caliper whereas Lima et al. and Rakesh B. Nair et al. used a simple caliper [8,22-24]. In Bangbose et al. studies, the assessment was performed on Day 1 and Day 2 where postoperative trismus (mouth opening) was recorded as the mean±standard deviation [22,23]. Both studies concluded that the relief of trismus was comparable acrosss all the groups. Similar findings were reported by Lima et al. and Rakesh B. Nair et al [24,25].

Risk of Bias

After quality assessment using the RoB 2 tool, a risk of bias for five studies was found. Out of five, four were of low risk; however, one was having some concerns (Figure 2). This concern was mainly due to a lack of open-label clinical trials.




FIGURE 2: Risk of bias assessment of included articles

Level of Evidence

The level of evidence for included studies was assessed by the Oxford Centre for evidence-based medicine. Included studies were randomized controlled trials, hence the level of evidence was Ib.

Discussion

Third molar surgeries are routine procedures performed in dental clinics with minimal complications. However, in certain cases, postoperative complications such as pain, swelling, trismus, and infection can occur. While these complications are typically short-term and resolve over time, they can become more severe and prolonged, causing discomfort and negatively impacting a patient's quality of life. Several factors contribute to the development of these symptoms, including patient demographics, oral hygiene, medication, compliance with postoperative instructions, presence of preexisting dental conditions, and surgical factors such as duration, complexity, and magnitude. Despite these factors, some patients continue to experience symptoms that require extended postoperative medication. Without appropriate medication, the severity of symptoms can worsen, leading to prolonged recovery times. Clinicians commonly prescribe analgesics to alleviate symptoms and promote postoperative recovery. However, the conventional practice of prescribing these drugs after surgery has not demonstrated significant advantages in reducing postoperative pain and recovery time.

To address this, clinicians have started implementing preemptive administration of analgesics. Ong et al. and Pektas OZ et al. examined preemptive analgesia using tramadol with ketorolac and diflunisal with lornoxicam, respectively, in the context of third molar extraction [27,28]. Both studies showed no statistically significant differences between the groups in terms of postoperative rescue analgesics intake and postop pain values. However, subsequent research revealed that diclofenac and dexamethasone were more effective in the reduction of pain and swelling, excluding trismus, as demonstrated by Bamgboos et al. [22,23]. A systematic review was conducted to assess the efficacy of preemptive analgesics, specifically diclofenac and dexamethasone. The review revealed that the combination of these medications was superior in reducing postoperative pain and swelling compared to diclofenac alone. These findings contradicted a

study by Joshi et al., which found no significant difference in postoperative dental pain among patients receiving preoperative ibuprofen, diclofenac, paracetamol with codeine, or placebo tablets. Similarly, Hyrkas et al. reported no significant difference in analgesic efficacy with preoperative oral administration of diclofenac sodium following third molar surgery [29]. However, a study by Bamgboos et al. supported the use of preemptive analgesia to prevent the amplification of pain after surgery [22,23].

The coadministration of corticosteroids with NSAIDs has been proposed as an effective technique to reduce postoperative inflammation. Cortisol and synthetic cortisol analogs can interfere with inflammatory processes, thereby suppressing characteristic symptoms. NSAIDs act by regulating prostaglandin synthesis, which is closely associated with pain, inflammation, and fever.

By inhibiting the cyclooxygenase enzyme system, NSAIDs effectively reduce prostaglandin production. Administering NSAIDs prior to surgery has shown particular effectiveness in alleviating postoperative pain. Another study by de Sousa Santos JA involving third molar surgery patients demonstrated reduced pain and swelling after taking a preemptive combination of medications, suggesting a synergistic effect [18]. The systematic review included pain outcomes assessed across five studies using three different evaluation scales. Irrespective of pain scales used for evaluations, all included studies reported a reduction in postoperative pain after preemptive administration of drugs either in combination or alone. One study by Lima et al. that used dexamethasone compared to diclofenac in pain reduction found that dexamethasone is better than diclofenac [24]. However, when dexamethasone and diclofenac were coadministered, the pain reduction was more compared to diclofenac alone. This could be because of the synergistic effect of both drugs which need to be studied in the future.

Facial swelling is another complication usually observed after third molar surgery due to inflammation and edema. The facial swelling usually involves the buccal and preauricular region, which often causes discomfort due to the involvement of inflammation of the muscle and mucoperiosteal flap. Therefore, it is important to have less inflammation to reduce facial swelling and discomfort. In the present systematic review, all studies except Simon et al. measured facial swelling after preemptive analgesia where dexamethasone and diclofenac were effective in reducing facial swelling [21]. This could be attributed to the anti-inflammatory properties of diclofenac. In one study by Lima et al., when dexamethasone and diclofenac were effect through suppression of inflammatory response [24]. However, dexamethasone should be used cautiously.

In third molar surgery, patients may have trismus due to mild injury medial pterygoid muscle during the inferior alveolar nerve block. Trismus usually causes a reduction in mouth opening and may persist for a longer duration affecting day-to-day activities like mastication and chewing. It is suggestive that preemptive medication may assist in reducing the trismus. However, the present systematic review did not find any evidence regarding the reduction of trismus irrespective of preemptive analgesia using a combination or single NSAIDs or steroids. The exact reason for this observation could not be ascertained. However, the development of trismus involves multiple factors such as acute inflammation, stripping of the lowest part of the temporalis tendon during flap elevation, traction of buccal flaps, spasmodic contraction of the medial pterygoid, multiple pricks/traumas during infiltration, which could explain this observation [30].

It is important to acknowledge certain limitations of this study. The included trials exhibited heterogeneity in terms of outcome evaluation, different time points, dosage, and mode of administration. Additionally, the sample size involved in these studies was relatively small, which limited our ability to identify meaningful differences. Furthermore, the use of different pain evaluation scales, such as the standard VAS, and Likert-type pointer category rating scale restricted our ability to conduct a meta-analysis.

Conclusions

Preemptive administration of dexamethasone and diclofenac has been shown to effectively reduce pain and facial swelling, with the exception of trismus, in third molar surgeries when compared to diclofenac alone. As a result, it is recommended to administer these drugs prior to the commencement of third molar extraction. However, it is important to note that further research is needed, specifically good quality randomized controlled trials involving large cohorts, in order to assess any significant variations and validate these findings.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Schultze-Mosgau S, Schmelzeisen R, Frölich JC, Schmele H: Use of ibuprofen and methylprednisolone for the prevention of pain and swelling after removal of impacted third molars. J Oral Maxillofac Surg. 1995, 53:2-7. 10.1016/0278-2391(95)90486-7
- Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021, 88:105906. 10.1016/j.ijsu.2021.105906
- Julian PT Higgins, James Thomas, Jacqueline Chandler, Miranda Cumpston, Tianjing Li, Matthew J, Matthew J Page: Cochrane handbook for systematic reviews of interventions. Julian PT Higgins (ed): Wiley, 2019. 10.1002/9781119536604
- Gorecki P, Rainsford KD, Taneja P, et al.: Submucosal diclofenac for acute postoperative pain in third molar surgery: a randomized, controlled clinical trial. J Dent Res. 2018, 97:381-7. 10.1177/0022034517744207
- Momesso GA, Grossi-Oliveira GA, Silva WP, et al.: A triple-blind randomized clinical trial of different associations between dexamethasone and non-steroids anti-inflammatories for preemptive action in third molar extractions. Sci Rep. 2021, 11:24445. 10.1038/s41598-021-04068-z
- Antunes AA, Avelar RL, Martins Neto EC, Frota R, Dias E: Effect of two routes of administration of dexamethasone on pain, edema, and trismus in impacted lower third molar surgery. Oral Maxillofac Surg. 2011, 15:217-23. 10.1007/s10006-011-0290-9
- Zupelari-Goncalves P, Weckwerth GM, Calvo AM, et al.: Efficacy of oral diclofenac with or without codeine for pain control after invasive bilateral third molar extractions. Int J Oral Maxillofac Surg. 2017, 46:621-7. 10.1016/j.ijom.2017.01.008
- Majid OW: Submucosal dexamethasone injection improves quality of life measures after third molar surgery: a comparative study. J Oral Maxillofac Surg. 2011, 69:2289-97. 10.1016/j.joms.2011.01.037
- Selimović E, Ibrahimagić-Šeper L, Šišić I, Sivić S, Huseinagić S: Prevention of trismus with different pharmacological therapies after surgical extraction of impacted mandibular third molar. Med Glas (Zenica). 2017, 14:145-51. 10.17392/871-16
- Çebi AT, Kasapoğlu MB: Effects of preemptive single dose sustained release non-steroidal antiinflammatory drugs on postoperative complications following third molar surgery. Konuralp Med J. 2021, 13:82-8. 10.18521/ktd.772556
- 11. Rangaswamy S, Sheshappa KN, Srikanthan R: Preemptive analgesic efficacy of diclofenac sodium for surgical removal of impacted third molars. Int J Health Sci. 2016, 7:38-41. 10.5005/jp-journals-10042-1033
- Satyanarayana KY, George M, Rajamoorthy SN: Comparison of the preemptive analgesic efficacy of submucosal and trans dermal patch form of diclofenac and its influence on post-operative discomfort in surgical removal of impacted third molars - a randomized control study. J Popul Ther Clin Pharmacol. 2022, 30:361-70. 10.47750/jptcp.2023.30.10.040
- Liporaci Junior JL: Assessment of preemptive analgesia efficacy in surgical extraction of third molars . Rev Bras Anestesiol. 2012, 62:502-10. 10.1016/S0034-709470148-4
- Brucoli M, De Andreis M, Bonaso M, Boffano P, Benech A: Comparative assessment of dexamethasone administration routes for the management of postoperative symptoms following third molar surgery. J Stomatol Oral Maxillofac Surg. 2019, 120:529-33. 10.1016/j.jormas.2019.03.004
- Priyanga R, Balamurugan R, Rajan PS: Comparison of dexamethasone administration through sublingual and intramuscular routes for evaluation of pain, swelling, and trismus after impacted mandibular third molar surgery - a prospective randomized controlled study. Oral Maxillofac Surg. 2022, 26:155-9. 10.1007/s10006-021-00978-4
- Lakhani KS, Joshi S, Pawar S, et al.: Evaluation of the efficacy of oral and intramuscular administration of dexamethasone on postoperative pain, swelling, and trismus after surgical removal of impacted third molar: a comparative split-mouth study. Cureus. 2023, 15:e38306. 10.7759/cureus.38306
- 17. Alcântara CE, Falci SG, Oliveira-Ferreira F, Santos CR, Pinheiro ML: Pre-emptive effect of dexamethasone and methylprednisolone on pain, swelling, and trismus after third molar surgery: a split-mouth randomized triple-blind clinical trial. Int J Oral Maxillofac Surg. 2014, 43:93-8. 10.1016/j.ijom.2013.05.016
- de Sousa Santos JA, da Silva LC, de Santana Santos T, Menezes Júnior LR, de Assunção Oliveira AC, Brandão JR: Comparative study of tramadol combined with dexamethasone and diclofenac sodium in third-molar surgery. J Craniomaxillofac Surg. 2012, 40:694-700. 10.1016/j.jcms.2012.01.001
- Orozco-Solís M, García-Ávalos Y, Pichardo-Ramírez C, Tobías-Azúa F, Zapata-Morales JR, Aragon-Martínez OH, Isiordia-Espinoza MA: Single dose of diclofenac or meloxicam for control of pain, facial swelling, and trismus in oral surgery. Med Oral Patol Oral Cir Bucal. 2016, 21:e127-34. 10.4317/medoral.20925
- Akbulut N, Üstüner E, Atakan C, Çölok G: Comparison of the effect of naproxen, etodolac and diclofenac on postoperative sequels following third molar surgery: a randomised, double-blind, crossover study. Med Oral Patol Oral Cir Bucal. 2014, 19:e149-56. 10.4317/medoral.19518
- Simone JL, Jorge WA, Horliana AC, Canaval TG, Tortamano IP: Comparative analysis of preemptive analgesic effect of dexamethasone and diclofenac following third molar surgery. Braz Oral Res. 2013, 27:266-71. 10.1590/S1806-83242013005000012
- Bamgbose BO, Akinwande JA, Adeyemo WL, Ladeinde AL, Arotiba GT, Ogunlewe MO: Effects of coadministered dexamethasone and diclofenac potassium on pain, swelling and trismus following third molar surgery. Head Face Med. 2005, 1:11. 10.1186/1746-160X-1-11
- 23. Bamgbose BO, Akinwande JA, Adeyemo WL, Ladeinde AL, Arotiba GT, Ogunlewe MO: Prospective, randomized, open-label, pilot clinical trial comparing the effects of dexamethasone coadministered with diclofenac potassium or acetaminophen and diclofenac potassium monotherapy after third-molar extraction in adults. Curr Ther Res Clin Exp. 2006, 67:229-40. 10.1016/j.curtheres.2006.07.001
- Lima TC, Bagordakis E, Falci SG, Dos Santos CR, Pinheiro ML: Pre-emptive effect of dexamethasone and diclofenac sodium associated with codeine on pain, swelling, and trismus after third molar surgery: a splitmouth, randomized, triple-blind, controlled clinical trial. J Oral Maxillofac Surg. 2018, 76:60-6. 10.1016/j.joms.2017.06.012
- 25. Nair RB, Rahman NM, Ummar M, Hafiz KA, Issac JK, Sameer KM: Effect of submucosal injection of

dexamethasone on postoperative discomfort after third molar surgery: a prospective study. J Contemp Dent Pract. 2013, 14:401-4. 10.5005/jp-journals-10024-1335

- Rodrigo MR, Rosenquist JB, Cheung LK: Paracetamol and diflunisal for pain relief following third molar surgery in Hong Kong Chinese. Int J Oral Maxillofac Surg. 1987, 16:566-71.
- 27. Ong KS, Tan JM: Preoperative intravenous tramadol versus ketorolac for preventing postoperative pain after third molar surgery. Int J Oral Maxillofac Surg. 2004, 33:274-8. 10.1006/ijom.2003.0515
- Pektas ZO, Sener M, Bayram B, et al.: A comparison of pre-emptive analgesic efficacy of diflunisal and lornoxicam for postoperative pain management: a prospective, randomized, single-blind, crossover study. Int J Oral Maxillofac Surg. 2007, 36:123-7. 10.1016/j.ijom.2006.10.005
- Hyrkäs T, Ylipaavalniemi P, Oikarinen VJ, Paakkari I: Preoperative intravenous diclofenac for postoperative pain prevention in outpatients. Br J Oral Maxillofac Surg. 1993, 31:351-4. 10.1016/0266-4356(93)90189-4
- Balakrishnan G, Narendar R, Kavin T, Venkataraman S, Gokulanathan S: Incidence of trismus in transalveolar extraction of lower third molar. J Pharm Bioallied Sci. 2017, 9:S222-7. 10.4103/jpbs.JPBS_161_17